BRAIN CANCER

Gallium maltolate now has been granted an orphan drug designation for adult and pediatric patients with glioblastoma multiforme.

An investigation of treatment with concurrent paxalisib and whole brain radiotherapy is underway in a phase 1 clinical trial.

A trial of targeted treatment with improved drug delivery to the brain met its primary end point for overall survival in patients with recurrent glioblastoma.

In a phase 1 study, anti-tumor responses were induced with PRT811 treatment in patients with recurrent, high-grade glioma and advanced or metastatic uveal melanoma.

New data show the promise for use of tovorafenib to reduce pre-treated pediatric patients with a low-grade glioma.

Katherine B. Peters, MD, PhD, discusses the findings from the phase 3 INDIGO trial which were presented at the 2023 ASCO annual meeting.

The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.

ACTION-1 is investigating RYZ101 versus standard-of-care therapy in patients with SSTR-positive gastroenteropancreatic neuroendocrine tumors after 177Lu-SSA therapy.

Manmeet Ahluwalia, MD, discusses results from the CRUX trial which were presented during the 2023 American Society of Clinical Oncology Annual Meeting.

Rupesh Kotecha, MD, discusses the key findings from an analysis centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.

In an interview with Targeted Oncology, Craig Horbinski, MD, PhD, discussed recent recommendations and NCCN guidelines regarding the molecular profiling of gliomas and other central nervous system cancers.

For Brain Cancer Awareness Month, Charles Redfern, MD, discussed the biggest technological changes to treatment for adult patients with brain cancer and how holistic treatment remains important for treating this challenging disease.

Two genetically engineered gamma-delta T-cell therapies, INB-400 and INB-410, have been granted an orphan drug designation from the FDA for numerous types of malignant glioma.

Rupesh Kotecha, MD, discusses results of an analysis which centered around the use of pulse reduced dose rate intensity-modulated radiotherapy in patients with central nervous system malignancies.

The first orphan drug designation from the FDA has been received by FORE Biotherapeutics and for the FORE8394 program for patients with primary brain and central nervous system malignancies.

Patrick Wen, MD, looks at how emerging evidence has shown promise for targeting mutations in patients with glioblastomas when it was once believed these therapies may not work for these patients.

Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.

Vorasidenib may break a 20-year gap in treatment advances for IDH-mutant low-grade glioma, according to phase 3 findings from the INDIGO study.

The FDA has granted the cell therapy temferon an orphan drug designation to treat patients with brain cancer.

Based on the FDA’s review of a new drug application, a phase 2 study will evaluate the safety and efficacy of azeliragon for patients with glioblastoma.

In an interview with Targeted Oncology, Patrick Wen, MD, discussed precision medicine for adult gliomas, including present and future treatment options.

In an interview with Targeted Oncology™, Manmeet Ahluwalia, MD, discussed the importance of the Inaugural Miami Cancer Institute Precision Medicine Oncology Symposium, what to expect from his presentation on brain metastases, and what to expect from presentations by other experts.

After more than 15 years with no new treatments for glioblastoma, a novel LSD1 small molecule has been granted orphan drug designation by the FDA.

Both pediatric brain cancers and sarcomas have an extremely dismal outcome in the relapse setting, according to Catherine Bollard, MD. A new Cancer Grand Challenge aims to address the issue with the development of new therapies.

Following positive data from the phase 1 ReSPECT-GBM trial, the first patient has been dosed with rhenium (186Re) obisbemeda in the phase 2 portion.

Azeliragon has been granted an orphan drug designation by the FDA for patients with glioblastoma after previous trials demonstrated the agent to be well-tolerated in Alzheimer’s disease.

Based on topline results from tovorafenib in the FIREFLY-1 study, the developer plans to file a new drug application with the FDA.

A prospective, blinded study confirmed the accuracy of the detecting brain tumors with the TriNetraTM-Glio test, addressing an unmet medical need for experts in this space.

Primary brain cancers are aggressive, resulting in low survival rates, and pose significant challenges to effective treatment, but ongoing studies signal hope for patients with there tumors.

DCVax-L was well tolerated and prolonged survival in patients with newly diagnosed and recurrent glioblastoma within the phase 3 trial.